UN&UP’s TheraLode™ nanoparticle thrombolysis platform for acute ischemic stroke selected to be part of the NIH’s Company Showcase at Life Science Summit

Written By Duke Creighton
 

UN&UP is excited to announce that its TheraLode™ nanoparticle thrombolysis platform for acute ischemic stroke has been selected to be part of the NIH’s Emerging Company Showcase at the Life Science Summit in New York City on October 11ᵗʰ, 2023. This honor is especially meaningful to us given that it is reserved for very few NIH-supported efforts.

The Life Sciences Summit (LSS) is an early-stage investor and business development conference that connects emerging biotech companies and academic innovators with the investors and strategic partners they will need to move their new discoveries through clinical development.

Duke Creighton
Previous

UN&UP’s Transformational CorBot™ Electrophysiology System was Awarded Participation into the Prestigious C3i Program by the NIBIB, NHLBI, and Coulter Foundation
Next

UN&UP Announces the Newest Member of our Fellowship Program: Matthew DeVenecia